Merck (MRK) Tops Q1 EPS by 16c, Revenues Beat; Lowers FY20 EPS/Revenue Guidance Below Consensus

Go back to Merck (MRK) Tops Q1 EPS by 16c, Revenues Beat; Lowers FY20 EPS/Revenue Guidance Below Consensus

Wall Street down on flight from techs; move to value limits loss on Dow, S&P 500

April 28, 2020 6:39 AM EDT

By Stephen Culp

NEW YORK (Reuters) - Wall Street's major indexes lost ground on Tuesday as investors moved out of market-leading growth stocks, though a rotation into cyclical value stocks indicated hopes of economic revival as states began to relax restrictions enacted to fight the deadly COVID-19 pandemic.

While technology stocks pulled all three major U.S. stock indexes into the red, they all remained within 20% of their February all-time highs.

"The stock market today is about money coming out of tech and going into economically sensitive value stocks, where prices have suffered the most," said Tim... More

Merck (MRK) calls more active than puts into EPS and outlook

April 27, 2020 10:45 AM EDT

Merck (NYSE: MRK) May weekly call option implied volatility is at 42, May is at 33; compared to its 52-week range of 15 to 64 into the expected release of quarter results before the bell on April 28. Call put ratio 2 calls to 1 put.

... More

Merck (MRK) Announces First Clinical Outcomes Evaluating Six-Week Dosing Schedule for KEYTRUDA Presented at AACR

April 27, 2020 6:57 AM EDT

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from Cohort B of KEYNOTE-555, a Phase 1 trial evaluating a 400 mg every six-week (Q6W) dosing regimen for KEYTRUDA, Mercks anti-PD-1 therapy, in patients with metastatic melanoma. Results of the study which represent the first clinical outcomes evaluating Q6W dosing for KEYTRUDA demonstrated efficacy and safety comparable to findings from previous melanoma trials evaluating KEYTRUDA monotherapy. Interim data showed an overall response rate (ORR) of 38.6% (n=17/44) (95% CI, 24.4-54.5) in patients who received KEYTRUDA... More

Merck (MRK), Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers

April 27, 2020 6:46 AM EDT

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the Institute for Systems Biology (ISB), today announced a new research collaboration to investigate and define the molecular mechanisms of SARS-CoV-2 infection and COVID-19 and identify targets for medicines and vaccines. Merck has also entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the U.S. Department of Health and Human Services, for BARDA to provide funding support for this research... More

Merck (MRK) Announces LYNPARZA Demonstrated OS Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

April 24, 2020 6:56 AM EDT

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced further positive results from the Phase 3 PROfound trial evaluating LYNPARZA in men with metastatic castration-resistant prostate cancer (mCRPC) who have a homologous recombination repair gene mutation (HRRm) and whose disease had progressed on prior treatment with new hormonal agent (NHA) treatments (e.g. enzalutamide or abiraterone).

Results from the trial showed a statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival (OS) with LYNPARZA vs. enzalutamide or abiraterone in men... More